$11.66
1.93%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
US28658R1068
Symbol
CLYM

Eliem Therapeutics Inc Target price 2026 - Analyst rating & recommendation

Eliem Therapeutics Inc Classifications & Recommendation

Buy
95%
Hold
5%

Eliem Therapeutics Inc Price Target

Target Price $22.44
Price $11.66
Potential
Number of Estimates 16
16 Analysts have issued a price target Eliem Therapeutics Inc 2027 . The average Eliem Therapeutics Inc target price is $22.44. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 21 analysts: 20 Analysts recommend Eliem Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Eliem Therapeutics Inc stock has an average upside potential 2027 of . Most analysts recommend the Eliem Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -0.88 -0.81
42.48% 7.95%
P/E negative

17 Analysts have issued a Eliem Therapeutics Inc forecast for earnings per share. The average Eliem Therapeutics Inc EPS is

$-0.81
unlock
. This is
8.00% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.74 1.33%
unlock
, the lowest is
$-0.84 12.00%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.88 42.48%
2026
$-0.81 7.95%
unlock
2027
$-1.00 23.46%
unlock
2028
$-1.27 27.00%
unlock
2029
$-2.27 78.74%
unlock
2030
$-2.52 11.01%
unlock
2031
$-2.07 17.86%
unlock
2032
$-0.48 76.81%
unlock
2033
$1.41 393.75%
unlock

P/E ratio

Current -15.85 373.54%
2026
-14.70 7.27%
unlock
2027
-11.94 18.78%
unlock
2028
-9.37 21.52%
unlock
2029
-5.23 44.18%
unlock
2030
-4.72 9.75%
unlock
2031
-5.74 21.61%
unlock
2032
-25.01 335.71%
unlock
2033
8.45 133.79%
unlock

Current Eliem Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Oppenheimer
Locked
➜
Locked
Locked Sep 08 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Sep 08 2026
B. Riley Securities
Locked
➜
Locked
Locked Sep 04 2026
BTIG
Locked
➜
Locked
Locked Sep 03 2026
Baird
Locked
➜
Locked
Locked Sep 03 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Aug 24 2026
Wedbush
Locked
➜
Locked
Locked Aug 19 2026
Analyst Rating Date
Locked
Oppenheimer:
Locked
➜
Locked
Sep 08 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Sep 08 2026
Locked
B. Riley Securities:
Locked
➜
Locked
Sep 04 2026
Locked
BTIG:
Locked
➜
Locked
Sep 03 2026
Locked
Baird:
Locked
➜
Locked
Sep 03 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Aug 24 2026
Locked
Wedbush:
Locked
➜
Locked
Aug 19 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today